Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Prelude Therapeutics (PRLD) EBITDA (2024 - 2025)

Prelude Therapeutics' EBITDA history spans 2 years, with the latest figure at -$16.5 million for Q4 2025.

  • For Q4 2025, EBITDA rose 43.0% year-over-year to -$16.5 million; the TTM value through Dec 2025 reached -$99.5 million, up 21.86%, while the annual FY2025 figure was -$99.5 million, 21.86% up from the prior year.
  • EBITDA for Q4 2025 was -$16.5 million at Prelude Therapeutics, up from -$19.7 million in the prior quarter.
  • Across five years, EBITDA topped out at -$16.5 million in Q4 2025 and bottomed at -$34.8 million in Q2 2024.